Cortical Excitability Measures May Predict Clinical Response to Fampridine in Patients with Multiple Sclerosis and Gait Impairment

Background: Most multiple sclerosis (MS) patients will develop walking limitations during the disease. Sustained-release oral fampridine is the only approved drug that will improve gait in a subset of MS patients. Objectives: (1) Evaluate fampridine cortical excitability effect in MS patients with g...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain Sci
Hauptverfasser: Ahdab, Rechdi, Shatila, Madiha M., Shatila, Abed Rahman, Khazen, George, Freiha, Joumana, Salem, Maher, Makhoul, Karim, El Nawar, Rody, El Nemr, Shaza, Ayache, Samar S., Riachi, Naji
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6956091/
https://ncbi.nlm.nih.gov/pubmed/31817319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/brainsci9120357
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge